The Ina Dcure Foundation
Non Profit Organization Management, 12 Scott Ct, Fairfield, New Jersey, 07004, United States, 1-10 Employees
Who is THE INADCURE FOUNDATION
The INADcure Foundation, is the only U.S. based nonprofit dedicated exclusively to the INAD community. The Foundations mission is to support the development of treatments, including a cur...
Read More
- Headquarters: 12 Scott Ct, Fairfield, New Jersey, 07004, United States
- Date Founded: 2017
- Employees: 1-10
- Revenue: Under $1 Million
- Active Tech Stack: See technologies
Industry: Non Profit Organization Management
SIC Code: 8641
Does something look wrong? Fix it. | View contact records from THE INADCURE FOUNDATION
The INADcure Foundation Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding The INADcure Foundation
Answer: The INADcure Foundation's headquarters are located at 12 Scott Ct, Fairfield, New Jersey, 07004, United States
Answer: The INADcure Foundation's official website is https://inadcure.org
Answer: The INADcure Foundation's revenue is Under $1 Million
Answer: The INADcure Foundation's SIC: 8641
Answer: The INADcure Foundation has 1-10 employees
Answer: The INADcure Foundation is in Non Profit Organization Management
Answer: The INADcure Foundation contact info: Phone number: Website: https://inadcure.org
Answer: The INADcure Foundation, is the only U.S. based nonprofit dedicated exclusively to the INAD community. The Foundations mission is to support the development of treatments, including a cure, for Infantile Neuroaxonal Dystrophy (INAD), a lysosomal storage disorder and other forms of PLA2G6-related neurodegeneration (PLAN). PLA2G6-related neurodegeneration (PLAN) is an umbrella term of three diseases caused by PLA2G6 loss. Infantile Neuroaxonal Dystrophy (INAD) is typically recognized in early childhood between the ages of 6 months and 2 years. A common pattern in young children is loss of previously acquired skills, mental and physical ability and progression of the disease over time. Atypical or Juvenile Neuroaxonal Dystrophy (aNAD) affects children at around age 4. The symptoms of individuals with aNAD are fairly stable during their early childhood but start declining between the ages of 7 and 12. A third form affects young adults who develop dystonia-parkinsonism. There is currently no cure for these diseases. We are actively forging partnerships with academic institutions, biotechnology and pharmaceutical companies to accelerate the development of new and pending treatments. In collaboration with our scientific advisors, we identify the most promising INAD research projects for partnership and funding. We work tirelessly in our efforts to fund the research that we hope will eradicate INAD, so that not one more child has to suffer from this devastating disease.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month